DOLTHERA is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease.

Our clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that we expect to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on DOLTHERA’s core decoy technology.